title: A phase II trial of paclitaxel, 5-fluorouracil (5-FU) and cisplatin in patients with metastatic or recurrent gastric cancer.
abstract: OBJECTIVE
  We wanted to assess the effectiveness and safety of combination chemotherapy with paclitaxel, 5-fluorouracil (5-FU) and cisplatin for treating advanced gastric cancer.
  
  
  METHODS
  Patients with metastatic or recurrent gastric cancer were entered into this study. Paclitaxel at a dose of 135 mg/m(2) on day 1, 5-FU 1 g/m(2)/day in a 24 hour continuous infusion from day 1 to day 4 and cisplatin 60 mg/m(2) on day 1 were administered. This regimen was repeated every 3 weeks.
  
  
  RESULTS
  A total of 34 patients were enrolled in this study. Among them, 33 patients were finally evaluable for their response. 17 (51.5%) patients had a partial response (95% CI: 26.0 approximately 77.0%). The median duration of overall survival was 13.2 months. Grade 3 or 4 neutropenia and thrombocytopenia were observed in 15.2% and 1.1% of all the cycles, respectively. Grade 3 stomatitis and neurotoxicity were observed in 20.6% and 1.1% of all patients, respectively. Grade 4 non-hematologic toxicity was not observed.
  
  
  CONCLUSIONS
  The regimen of paclitaxel, 5-FU and cisplatin demonstrated activity and acceptable toxicity for treating metastatic gastric cancer.
authors.affiliation: Department of Internal Medicine, College of Medicine, Inje University, Sanggye Paik Hospital, Seoul, Korea.
authors.forename: Gun Hi
authors.initials: GH
authors.lastname: Kang
authors.forename: Gwang Sil
authors.initials: GS
authors.lastname: Kim
authors.forename: Hyo Rak
authors.initials: HR
authors.lastname: Lee
authors.forename: Young Jin
authors.initials: YJ
authors.lastname: Yuh
authors.forename: Sung Rok
authors.initials: SR
authors.lastname: Kim
references.citation: J Prev Med Public Health. 2008 Mar;41(2):92-9
references.pmid: 18385549
references.citation: Anticancer Drugs. 1998 Apr;9(4):307-10
references.pmid: 9635920
references.citation: Ann Oncol. 1997 Feb;8(2):163-8
references.pmid: 9093725
references.citation: J Clin Oncol. 2007 Aug 1;25(22):3217-23
references.pmid: 17664469
references.citation: Ann Oncol. 2001 Jan;12(1):47-51
references.pmid: 11249048
references.citation: Br J Cancer. 1994 Aug;70(2):380-3
references.pmid: 7914428
references.citation: Jpn J Clin Oncol. 2005 Dec;35(12):720-6
references.pmid: 16332718
references.citation: J Clin Oncol. 1991 Sep;9(9):1692-703
references.pmid: 1678780
references.citation: J Clin Oncol. 2003 Jan 1;21(1):54-9
references.pmid: 12506170
references.citation: Am J Clin Oncol. 1998 Aug;21(4):416-9
references.pmid: 9708646
references.citation: Br J Cancer. 1995 Mar;71(3):587-91
references.pmid: 7533517
references.citation: J Natl Cancer Inst. 2005 Oct 5;97(19):1407-27
references.pmid: 16204691
references.citation: Cancer. 1993 Jun 15;71(12):3813-8
references.pmid: 8508349
references.citation: Cancer. 1999 Jan 15;85(2):295-301
references.pmid: 10023695
references.citation: Korean J Intern Med. 2005 Jun;20(2):135-40
references.pmid: 16134768
references.citation: Gastric Cancer. 2005;8(2):64-70
references.pmid: 15864711
references.citation: J Clin Oncol. 2007 Aug 1;25(22):3210-6
references.pmid: 17664468
references.citation: Ann Oncol. 2003;14 Suppl 2:ii41-4
references.pmid: 12810457
references.citation: Cancer J Sci Am. 1998 Jul-Aug;4(4):269-74
references.pmid: 9689986
references.citation: J Clin Oncol. 2006 Nov 1;24(31):4991-7
references.pmid: 17075117